[Pathophysiology of hematological malignancies associated with ASXL1 mutations].

Abstract excerpt

Somatic mutations in the epigenetic regulator ASXL1 are considered a poor prognostic factor in myeloid malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASXL1 mutations coexist with other mutations in majority of patients, suggesting that its mutation alone is insufficient to cause cancer. ASXL1 mutations have been detected in age-related clonal hematopoiesis (CH), which has...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hematologic Neoplasms
• Share to Hematopoiesis
• Share to Leukemia, Myeloid, Acute